Caricamento quotazioni...
Previsioni
| Acquista |
8 |
| Mantieni |
2 |
| Vendi |
0 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
Oncolytics: Preclinical efficacy of Pelareorep in combination with a pan‑RAS inhibitor
Oncolytics reports preclinical data showing that Pelareorep combined with a pan‑RAS inhibitor reduced tumor growth in a RAS‑driven colorectal cancer model during the initial intensive dosing phase. There was no evidence of antagonism between Pelareorep and RAS inhibition, but the additive effect was smaller after switching to weekly Pelareorep dosing. The company plans to evaluate additional dosing schedules and RAS‑driven tumor models. Pelareorep is an intravenous immunotherapy in clinical development and has FDA Fast Track status for several gastrointestinal indications. » Altro su de.investing.com
FDA dialogue about approval pathway drives Oncolytics Biotech stock
Oncolytics Biotech has announced a "Type D" meeting with the FDA for early August to discuss adding a randomized part B to the REO 033 study, intended to support both accelerated and full approvals for pelareorep. Part B would retain the existing study design, increase the number of participants and incorporate a blinded independent central review to generate randomized efficacy data without starting a separate trial. The company reports progress in part A (target: 60 patients): about half of the sites are expected to be activated by the end of July and more than 20 patients have been pre-identified; full site activation is planned by the end of August. Oncolytics expects a first tumor response update from part A by the end of 2026 and, subject to FDA feedback, aims to begin recruitment for part B in the first quarter of 2027. » Altro su de.investing.com
Oncolytics schedules FDA Type C meeting on approval pathway for pelareorep in anal cancer
Oncolytics has set a Type C meeting with the FDA for April 16 to discuss a registration‑relevant, single‑arm study plan for pelareorep plus a checkpoint inhibitor in squamous cell carcinoma of the anus in second‑line and later therapy. The planned study would include around 60–70 patients with objective response rate (ORR) as the primary endpoint; earlier data (GOBLET cohort 4) showed an ORR of ~30% with a median duration of response of 17 months versus real‑world rates of 10–14%. The company has a market capitalization of USD 111.52 million, reported a negative free cash flow of USD 26.48 million over the past twelve months, and is given a weak financial rating by InvestingPro. » Altro su de.investing.com
Oncolytics Biotech completes first step in relocating its registered office to British Columbia
Oncolytics Biotech has completed the first part of its planned relocation and moved its jurisdiction of incorporation from Alberta to British Columbia via a process described as a “continuance.” The common shares, company name and NASDAQ trading symbol remain unchanged; the CUSIP and ISIN will remain the same until the completion of the second phase. Shareholders approved the move on January 15, 2026; the second phase foresees a transfer to Nevada effective March 31, 2026, after which the CUSIP and ISIN will change and outstanding shares will be converted into U.S. par value shares. The company adopted new articles of incorporation in British Columbia that differ in part from its previous founding documents. » Altro su de.investing.com
FDA grants Fast-Track for Pelareorep — Oncolytics stock jumps sharply
The FDA has granted Fast Track status to Oncolytics' Pelareorep for treatment of metastatic colorectal cancer with KRAS mutation and MSS in the second-line setting. Clinical data showed an objective response rate of 33% vs about 10% for standard therapies, as well as significantly better median PFS and OS. Oncolytics plans a controlled study starting in March, with first interim results expected by the end of 2026; the addressable market is estimated at USD 3–5 billion annually. » Altro su de.investing.com
Dati finanziari dell'azienda
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 0 | - |
| Utile lordo | -15,01K | - |
| Utile netto | -8,57 Mln | 35,31% |
| EBITDA | -8,6 Mln | 44,68% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 31,03 Mln € |
Numero di azioni | 100,36 Mln |
Massimo/minimo a 52 settimane | 1,18 € - 0,31 € |
| Dividendi | No |
Beta | 1,24 |
Rapporto P/E | -1,21 |
Rapporto PEG | 0,26 |
Rapporto P/B | -5,79 |
Rapporto P/S | 0,00 |
Profilo aziendale
Oncolytics Biotech Inc., una società biofarmaceutica in fase di sviluppo, si occupa della scoperta e dello sviluppo di prodotti farmaceutici per il trattamento del cancro. Il suo prodotto di punta è il pelareorep, un agente immunoterapico somministrato per via endovenosa per il trattamento dei tumori solidi e delle neoplasie ematologiche. Oncolytics Biotech Inc. ha un accordo di co-sviluppo con Merck KGaA e Pfizer Inc. per co-sviluppare il pelareorep in combinazione con paclitaxel e avelumab, un anticorpo umano anti-PD-L1 per il trattamento del carcinoma mammario metastatico positivo ai recettori ormonali e negativo al recettore 2 del fattore di crescita epidermico umano; e con PrECOG LLC. La società è stata costituita nel 1998 ed ha sede a Calgary, in Canada.
| Nome | Oncolytics Biotech |
| CEO | Jared Kelly |
| Sede centrale | San Diego,
ca Canada |
| Sito web | |
| Settore | Materiali |
| Industria | Prodotti chimici |
| Quotazione in borsa | 05/10/2001 |
| Dipendenti | 29 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
Toronto Stock Exchange | ONC.TO |
NASDAQ | ONCY |
Frankfurt | ONYN.F |